Cardiovascular effects of sodium–glucose cotransporter 2 inhibitors: multiple actions

"Cardiovascular effects of sodium–glucose cotransporter 2 inhibitors: multiple actions." Current Medical Research and Opinion, 32(9), pp. 1513–1514

Transparency

Declaration of funding

This letter was written independently. The authors did not receive financial or professional help with the preparation of the manuscript.

Declaration of financial/other relationships

N.K. has disclosed that she has given talks, attended conferences and participated in trials sponsored by Amgen, Astra Zeneca, MSD, Novo Nordisk, Novartis and Sanofi. V.G.A. has disclosed that he has given talks, attended conferences and participated in trials sponsored by Amgen, Sanofi, MSD, Lilly and Angelini. D.P.M. has disclosed that he has given talks and attended conferences sponsored by MSD, AstraZeneca and Libytec.